Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study

被引:12
作者
Zhao, Chenghao [1 ]
Xiang, Zhanwang [1 ]
Li, Mingan [1 ]
Wang, Haofan [1 ]
Liu, Huan [1 ]
Yan, Huzheng [1 ]
Huang, Mingsheng [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Intervent Radiol, Guangzhou 510630, Peoples R China
关键词
atezolizumab plus bevacizumab; lenvatinib; transarterial chemoembolization; hepatocellular carcinoma; efficacy; T-CELL; CANCER; PD-L1;
D O I
10.2147/JHC.S418256
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Combined transarterial chemoembolization (TACE) and Lenvatinib (LEN) treatment (LEN-TACE) has been shown to be beneficial. We aimed to evaluate retrospectively Atezolizumab plus Bevacizumab (Atezo/Bev)-TACE compared with LEN-TACE as a first-line therapy for unresectable HCC.Patients and Methods: From October 2020 to October 2022, data from 98 consecutive HCC patients were analyzed. After propensity score matching, two cohorts of 34 patients who received either Atezo/Bev-TACE or LEN-TACE were studied. We compared overall survival (OS), progression-free survival (PFS), duration of response, objective response rate (ORR) and disease control rate (DCR) based on RECIST 1.1 and mRECIST, as well as safety outcome between the two cohorts. Results: The 6-month and 12-month OS rates were 85.3% (95% CI 73.5-97.0) and 75.4% (95% CI 53.6-85.7) in the Atezo/BevTACE group, and 88.2% (95% CI 76.5-97.1) and 79.2% (95% CI 63.6-90.9) in the LEN-TACE group, respectively. The hazard ratio for death in the Atezo/Bev-TACE group compared to the LEN-TACE group was 1.09 (95% CI 0.47-2.51; P = 0.837). The median PFS was 7.03 months (95% CI 3.89-10.17) in the Atezo/Bev-TACE group and 6.03 months (95% CI 0-14.14) in the LEN-TACE group (HR 1.21; 95% CI 0.66-2.21; P = 0.545). No significant difference in ORR and DCR between the two groups was observed either according to RECIST 1.1 or mRECIST standards. Incidence rates of hand-foot skin reaction (35.3% vs 5.9%, P = 0.003) and proteinuria (17.9% vs 2.9%, P = 0.046) were significantly higher in the LEN-TACE group.Conclusion: Atezo/Bev-TACE and LEN-TACE showed comparable efficacy and safety as first-line therapies for unresectable HCC patients.
引用
收藏
页码:1195 / 1206
页数:12
相关论文
共 32 条
  • [1] Baecker A, 2018, EUR J CANCER PREV, V27, P205, DOI [10.1097/CEJ.0000000000000428, 10.1097/cej.0000000000000428]
  • [2] Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
    Casadei-Gardini, Andrea
    Rimini, Margherita
    Tada, Toshifumi
    Suda, Goki
    Shimose, Shigeo
    Kudo, Masatoshi
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Lim, Ho Yeong
    Rimassa, Lorenza
    Presa, Jose
    Masi, Gianluca
    Yoo, Changhoon
    Lonardi, Sara
    Tovoli, Francesco
    Kumada, Takashi
    Sakamoto, Naoya
    Iwamoto, Hideki
    Aoki, Tomoko
    Chon, Hong Jae
    Himmelsbach, Vera
    Pressiani, Tiziana
    Montes, Margarida
    Vivaldi, Caterina
    Solda, Caterina
    Piscaglia, Fabio
    Hiraoka, Atsushi
    Sho, Takuya
    Niizeki, Takashi
    Nishida, Naoshi
    Steup, Christoph
    Iavarone, Massimo
    Di Costanzo, Giovanni
    Marra, Fabio
    Scartozzi, Mario
    Tamburini, Emiliano
    Cabibbo, Giuseppe
    Foschi, Francesco Giuseppe
    Silletta, Marianna
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    [J]. EUROPEAN JOURNAL OF CANCER, 2023, 180 : 9 - 20
  • [3] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [4] European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
  • [5] Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients
    Facciorusso, Antonio
    Licinio, Raffaele
    Muscatiello, Nicola
    Di Leo, Alfredo
    Barone, Michele
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (16) : 2009 - 2019
  • [6] Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal
    Fife, Brian T.
    Pauken, Kristen E.
    Eagar, Todd N.
    Obu, Takashi
    Wu, Jenny
    Tang, Qizhi
    Azuma, Miyuki
    Krummel, Matthew F.
    Bluestone, Jeffrey A.
    [J]. NATURE IMMUNOLOGY, 2009, 10 (11) : 1185 - U70
  • [7] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed O.
    Li, Daneng
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Mulla, Sohail
    Wang, Yulei
    Lim, Ho Yeong
    Zhu, Andrew X.
    Cheng, Ann-Lii
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) : 1894 - 1905
  • [8] Hepatocellular carcinoma
    Forner, Alejandro
    Reig, Maria
    Bruix, Jordi
    [J]. LANCET, 2018, 391 (10127) : 1301 - 1314
  • [9] Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
    Freeman, GJ
    Long, AJ
    Iwai, Y
    Bourque, K
    Chernova, T
    Nishimura, H
    Fitz, LJ
    Malenkovich, N
    Okazaki, T
    Byrne, MC
    Horton, HF
    Fouser, L
    Carter, L
    Ling, V
    Bowman, MR
    Carreno, BM
    Collins, M
    Wood, CR
    Honjo, T
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) : 1027 - 1034
  • [10] NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES
    Goel, Shom
    Duda, Dan G.
    Xu, Lei
    Munn, Lance L.
    Boucher, Yves
    Fukumura, Dai
    Jain, Rakesh K.
    [J]. PHYSIOLOGICAL REVIEWS, 2011, 91 (03) : 1071 - 1121